It is very uncertain whether FLUPHENAZINE DECANAOTE changes leaving the study early compared with FLUPHENAZINE ENANTHATE (very low certainty).
It is very uncertain whether FLUPHENAZINE DECANOATE changes leaving the study early compared with PLACEBO (very low certainty).
It is very uncertain whether adjunctive lithium + antipsychotics changes acceptability of treatment leaving early due to any reason compared with placebo/no adjunctive treatment + antipsychotics (very low certainty).
Lithium as sole treatment showed no clear difference in acceptability of treatment leaving early due to any reason compared with placebo (low certainty).
It is very uncertain whether lithium changes acceptability of treatment leaving early due to any reason compared with antipsychotics (very low certainty).
SUPPORTIVE THERAPY showed no clear difference in leaving the study early compared with ANY OTHER PSYCHOLOGICAL OR PSYCHOSOCIAL TREATMENT (moderate certainty).
SUPPORTIVE THERAPY showed no clear difference in leaving the study early compared with COGNITIVE BEHAVIOURAL THERAPY (moderate certainty).
It is very uncertain whether SUPPORTIVE THERAPY changes leaving the study early compared with FAMILY THERAPY (very low certainty).
It is very uncertain whether SUPPORTIVE THERAPY changes leaving the study early compared with PSYCHOEDUCATION (very low certainty).
It is very uncertain whether SUPPORTIVE THERAPY changes leaving the study early compared with STANDARD CARE (very low certainty).
It is very uncertain whether TEMPOROPARIETAL TMS changes adverse effects: Leaving the study early compared with STANDARD TREATMENT (very low certainty).
PREFRONTAL TMS showed no clear difference in adverse effects: Leaving the study early compared with SHAM TMS (low certainty).
PREFRONTAL TBS TMS showed no clear difference in adverse effects: Leaving the study early compared with SHAM TMS (low certainty).
TEMPOROPARIETAL TMS showed no clear difference in adverse effects: Leaving the study early compared with SHAM TMS (low certainty).
Adjunct cognitive behavioural therapy showed no clear difference in adverse event: Leaving the study early compared with adjunct supportive psychotherapy (moderate certainty).
Haloperidol showed no clear difference in leaving the study early due to any reason as a measure of overall… compared with first‐generation antipsychotics (low certainty).
It is very uncertain whether haloperidol changes leaving the study early due to inefficacy of treatment as a measure… compared with first‐generation antipsychotics (very low certainty).
It is very uncertain whether haloperidol changes leaving the study early due to adverse events as a measure of… compared with first‐generation antipsychotics (very low certainty).
It is very uncertain whether haloperidol changes leaving the study early due to any reason as a measure of overall… compared with first‐generation antipsychotics (very low certainty).